Evidence map›Paper›PMID 36265853›Full record

ArticleThe Journal of infectious diseases2022

Insights From Studies of the Genetics, Pathogenesis, and Immunogenicity of the Varicella Vaccine.

Ann M Arvin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Ann M ArvinDepartments of Pediatrics and Microbiology and Immunology, Stanford University School of Medicine, Stanford, California, USA.

Funding

Varicella-Zoster Virus: T Cell/Skin Tropisms &ImmunityR01AI020459 · NIAID · STANFORD UNIVERSITY · PI OLIVER, STEFAN LYNE · 1985 to 2023
$6.4M
Varicella zoster virus: molecular controls of cell fusion-dependent pathogenesisR01AI102546 · NIAID · STANFORD UNIVERSITY · PI ARVIN, ANN · 2012 to 2016
$1.9M
NIAID NIH HHS R01 AI020459NIAID NIH HHS R01 AI102546NIH HHS R01
6 · The paper itself

Abstract

While the varicella vaccine was created with approaches established for other live attenuated viral vaccines, novel methods to probe virus-host interactions have been used to explore the genetics, pathogenesis, and immunogenicity of the vaccine compared to wild-type varicella-zoster virus (VZV). As summarized here, a mechanism-based understanding of the safety and efficacy of the varicella vaccine has been achieved through these investigations.

Indexed as

Herpes ZosterHerpes Zoster VaccineViral VaccinesAntigens, ViralChickenpox VaccineHerpesvirus 3, HumanHumansVaccines, AttenuatedAntigens, ViralChickenpox VaccineHerpes Zoster VaccineVaccines, AttenuatedViral Vaccinesherpesvirusvaricella vaccinevaricella-zoster virusvaricella-zoster virus pathogenesis

Identifiers

PMID36265853
PMCPMC10205899

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.